Harald Rau

This inventor holds 57 USPTO granted patents and 40 published patent applications and 36 EPO patents, primarily in Controlled-Release Prodrugs (CPC class A61K). Top assignees: Ascendis Pharma A/s, Ascendis Pharma Growth Disorders A/s, Ascendis Pharma Endocrinology Division A/s. Active years: 2011-2026.

USPTO Granted Patents = 57 (Patent Applications = 40)

% Patents Active = 82.5

EPO Patents = 36 (Patent Applications = 56)

Average Co-Inventor Count = 4.7

ph-index = 10

Forward Citations = 401(Granted Patents)

Forward Citations (Not Self Cited) = 271(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Heidelberg, DE (2011 - 2023)
Dossenheim, DE (2011 - 2024)

Company Filing History:

Ascendis Pharma Growth Disorders A/s

patents

7 out of 9

Ascendis Pharma Endocrinology Division A/s

patents

4. 5 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

Ascendis Pharma Growth Disorders Division A/s

patents

7. 1 out of 1

Ascendis Pharma Endocrinology Division

patent

8. 1 out of 1

Ascendis Pharma Ophthalmology Division A/s

patent

9. 1 out of 1

Complex Biosystems Gmbh

patent

10. 1 out of 3

Graffinity Pharmaceuticals Ag

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Controlled-Release

Prodrugs

CNP Agonists

Growth Hormone

Hydrogel

PEGylation

Biodegradable

Polymeric

Sustained Release

Drug Delivery

Aminoalkyl Glycine

Ocular Treatments

57 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12544428 - CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS (2026-02-10),

2. 12274737 - PEGylated recombinant human growth hormone compounds (2025-04-14),

3. 12246070 - Hydrogel cross-linked hyaluronic acid prodrug compositions and methods (2025-03-11),

4. 12239689 - Controlled-release CNP agonists with low initial NPR-B activity (2025-03-04),

5. 12226457 - Dry growth hormone composition transiently linked to a polymer carrier (2025-02-18),

6. 12156917 - CNP prodrugs with carrier attachment at the ring moiety (2024-12-03),

7. 12133883 - Polymeric hGH prodrugs (2024-11-05),

8. 12083182 - Controlled-release CNP agonists with increased NEP stability (2024-09-10),

9. 11642415 - Hydrogel cross-linked hyaluronic acid prodrug compositions and methods (2023-05-09),

10. 11633487 - Prodrugs comprising an aminoalkyl glycine linker (2023-04-25),

11. 11559482 - Biodegradable polyethylene glycol based water-insoluble hydrogels (2023-01-24),

12. 11413351 - CNP prodrugs with carrier attachment at the ring moiety (2022-08-16),

13. 11389511 - Controlled-release CNP agonists with reduced side-effects (2022-07-19),

14. 11389510 - Controlled-release CNP agonists with low initial NPR-B activity (2022-07-19),

15. 11311604 - Controlled-release CNP agonists with low NPR-C binding (2022-04-26),

Title: Harald Rau: Pioneering Inventor from Dossenheim

Introduction: Harald Rau is a distinguished inventor hailing from Dossenheim, Germany, known for his groundbreaking contributions to the field of innovations and patents.

Latest Patents: Harald Rau holds several recent patents in various technological domains, showcasing his continuous commitment to pushing the boundaries of invention and creativity.

Career Highlights: Throughout his illustrious career, Harald Rau has demonstrated a remarkable ability to transform innovative ideas into tangible inventions that have significantly impacted the industry.

Collaborations: Harald Rau has collaborated with leading research institutions, universities, and companies worldwide, fostering a culture of innovation and knowledge exchange that has led to remarkable advancements in the field.

Conclusion: Harald Rau's relentless pursuit of innovation and his passion for creating solutions to complex problems have solidified his reputation as a visionary inventor in Dossenheim and beyond.